Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO)
Hospital
Location:
Catania,
Italy (IT)
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial (2025)
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, et al.
Journal article
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial (2023)
Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, et al.
Journal article